Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

ClinicalTrials.gov ID: NCT02237196

Public ClinicalTrials.gov record NCT02237196. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 7:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (ITN057AD)

Study identification

NCT ID
NCT02237196
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
121 participants

Conditions and interventions

Interventions

  • AMG 157 Biological
  • AMG 157 Placebo Biological
  • Cat Immunotherapy Biological
  • Cat Immunotherapy Placebo Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2, 2015
Primary completion
Mar 3, 2019
Completion
Mar 3, 2019
Last update posted
May 5, 2020

2015 – 2019

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
University of California, Los Angeles Los Angeles California 90025
National Jewish Health Denver Colorado 80206
Northwestern University Chicago Illinois 60611
University of Chicago Chicago Illinois 60637
Johns Hopkins Asthma & Allergy Center Baltimore Maryland 21231
University of North Carolina, Chapel Hill Chapel Hill North Carolina 27599
Vital Prospects Clinical Research Institute, P.C. Tulsa Oklahoma 74136
ASTHMA Inc. Clinical Research Center Seattle Washington 98115
University Wisconsin, Madison Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02237196, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2020 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02237196 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →